Leadership

Bluestar Genomics celebrates multi-disciplinary collaboration focused on a shared goal to benefit patients’ lives.

I am inspired by scaling truly innovative companies centered around the most urgent patient needs. With a laser focus on science and corporate development, companies can thrive while improving patient lives.

Dave Mullarkey

Chief Executive Officer

Dave is a life sciences industry veteran with an extensive track record of success across the life sciences industry of scaling and delivering value with therapeutic, diagnostic, and life science tools companies in both private and public settings. Most recently, he was president and chief executive officer of Omniome, where he guided and scaled the DNA sequencing company from the early technology development stage through the delivery of its beta prototype and ultimately leading to its sale to PacBio in 2021. Prior to Omniome, Dave served as the president and chief operating officer of Ariosa Diagnostics, a diagnostics company focused on the cell-free DNA non-invasive prenatal testing that was acquired by Roche in 2014. Post-acquisition, Dave served as lifecycle leader, site head, and a core member of the Roche Sequencing Solutions leadership team. He has also held positions at Johnson & Johnson, Eli Lilly and Company, Valeant Pharmaceuticals, and Dow Pharmaceuticals Sciences.

I am inspired by scaling truly innovative companies centered around the most urgent patient needs. With a laser focus on science and corporate development, companies can thrive while improving patient lives.
Translating complex biology and technology into valuable patient-centric products is what excites me the most.

Samuel Levy, PhD

Chief Scientific Officer

Sam joined Bluestar Genomics at its inception and has co-authored many of the research papers we have published about our epigenomics technology platform and our DNA-based 5-hydroxymethylcytosine (5hmC) biomarker. For more than 20 years he has held leadership positions in genomics and molecular diagnostic development at companies including Celera, Genomic Health, Quanticel Pharmaceuticals (now part of Celgene), and Impact Genomics/Lexent Bio which he co-founded and is now a part of Foundation Medicine. Samuel has also served on the faculty at the J. Craig Venter Institute, Scripps Translational Science Institute and Scripps Research Institute. He holds degrees from the University of Bristol and the University of Leeds in the United Kingdom.

Translating complex biology and technology into valuable patient-centric products is what excites me the most.
I am inspired to apply advances in technology toward the development of tests that find cancer more effectively and enable treatment to save lives.

Kelly Bethel, MD

Chief Medical Officer

Kelly has 20 years of experience as an AP/CP boarded practicing pathologist and hematopathologist, specializing in the diagnosis of blood cancers. She was a senior clinical investigator for an NIH-funded research center investigating circulating tumor cells in people with cancer. She co-founded Epic Sciences, where she was the initial lab director and led CLIA/CAP certification for a liquid biopsy assay using circulating tumor cells. Kelly holds degrees from Yale University and George Washington University School of Medicine.

I am inspired to apply advances in technology toward the development of tests that find cancer more effectively and enable treatment to save lives.
I am amazed by the rapid advances in the field of genomics and leveraging those learnings to early cancer detection to help deliver treatments sooner and save patients' lives.

Jim Vaughn, RPh

Chief Commercial Officer

Jim has more than 20 years of experience directing the global commercialization of molecular diagnostics and cancer therapeutics in oncology at companies including Searle/Pfizer and Genomic Health/Exact Sciences. He was chief commercial officer and global market lead for Oncotype DX breast, colorectal and prostate cancer products. In his more than two decades in the industry, he has developed a breadth of expertise in sales, marketing, product development, medical affairs and reimbursement strategy. Working and living internationally, Vaughn launched both diagnostic and therapeutic oncology, hematology, and urology products. Jim earned his MBA from the Kellogg School of Business at Northwestern and holds a BS in Pharmacy from Creighton University.

I am amazed by the rapid advances in the field of genomics and leveraging those learnings to early cancer detection to help deliver treatments sooner and save patients' lives.
I feel privileged to help the Bluestar Genomics team develop breakthrough technologies to improve patient care.

Wayne Volkmuth, PhD

Senior Vice President, Informatics & Data Discovery

Wayne has more than 20 years of experience in bioinformatics, genomics and drug discovery. He cofounded Atreca and Innectus, and held leadership positions at Renovis (now part of Evotec), Ceres, and Incyte Pharmaceuticals. Wayne has been granted US patents and has co-authored multiple peer-reviewed publications. He holds degrees from Stanford University, Princeton University, and University of Minnesota.

I feel privileged to help the Bluestar Genomics team develop breakthrough technologies to improve patient care.
Working at Bluestar Genomics since its inception, I continue to be inspired and motivated by the common goal I share with my incredibly talented colleagues: to help make all cancers treatable through early detection.

Anna Bergamaschi, PhD

Vice President, Product Development

Anna has over a decade of experience in next-generation sequencing assay workflows and has worked as a senior scientist at Bluestar Genomics. Previously, at Genomic Health, she led the technical development of blood-based liquid biopsy assay. Anna holds a PhD in Molecular Oncology from the University of Oslo, Norway in collaboration with Stanford where she spent most of her time in the optimization of array CGH. She holds a Master’s in Medical Biotechnology from the University of Modena School of Medicine, Italy.

Working at Bluestar Genomics since its inception, I continue to be inspired and motivated by the common goal I share with my incredibly talented colleagues: to help make all cancers treatable through early detection.
It's paramount that we make cutting-edge medical innovations accessible to patients whose lives can be prolonged through early diagnosis of cancer.

Danielle Scelfo, MHSA

Vice President, Market Access & Health Policy

Danielle is an accomplished health policy strategist leading teams across government affairs, market access, and reimbursement for over 25 years in biotech. Her extensive subject matter expertise guided innovative payment reforms across precision medicine diagnostics during her tenure at Sanofi Aventis, Genomic Health, Adaptive Biotechnologies, and Hologic. A principal voice in diagnostic health policy, Danielle has chaired the Coalition for 21st Century Medicine Reimbursement and Policy Workgroup, the California Healthcare Institute Diagnostic Workgroup, and participated in several CPT working groups for the American Medical Association. A member of leading federal and state diagnostic trade associations, Danielle earned her Master’s in Health Administration at Florida International University and a Bachelor of Science in Marketing from the University of Florida.

It's paramount that we make cutting-edge medical innovations accessible to patients whose lives can be prolonged through early diagnosis of cancer.
Cancer has affected or will affect everyone very personally in their lifetimes. I am thrilled to have the opportunity to apply my technology expertise in life sciences to Bluestar Genomics’ cancer detection mission.

Eric Nilson

Vice President, Enterprise IS&T

Eric has more than 20 years of experience directing IT for life sciences companies including Response Genetics Inc., Cypress Bioscience Inc., Suneva Medical Inc., and Orchestra Therapeutics Inc. He holds a B.S. in Business Administration/Information and Decision Systems from San Diego State University. He also served in the U.S. Marine Corps.

Cancer has affected or will affect everyone very personally in their lifetimes. I am thrilled to have the opportunity to apply my technology expertise in life sciences to Bluestar Genomics’ cancer detection mission.
Driven by passion for patients, we are committed to using our combined scientific, clinical, and automation expertise to help physicians detect cancers early, when their patients can still be treated.

Shimul Chowdhury, PhD, FACMG

Vice President, Laboratory Operations

Shimul has served as a clinical laboratory director in multiple laboratories including Rady Children’s institute for Genomic Medicine (RCIGM), Illumina Inc. and Quest Diagnostics. He has dedicated his career to implementing new genomic technologies to improve patient care and outcomes. He is a board-certified clinical molecular geneticist and licensed as a laboratory director in California, Florida and New York. He has authored over 30 peer-reviewed publications.

Driven by passion for patients, we are committed to using our combined scientific, clinical, and automation expertise to help physicians detect cancers early, when their patients can still be treated.
A commitment to fierce innovation and a shared passion for improving human health inspires this team to forge ahead with patient interest at the core of everything we do.

Victoria Steiner

Vice President, Corporate Communications

Victoria has more than 15 years of experience in biotech/healthcare communications and has held leadership roles at Synthego, Genomic Health, Healthline, Sutter Health and NASA. She holds a Master’s in Public and Business Administration from California State University, San Jose and a BA in Journalism from the University of California, Berkeley.

A commitment to fierce innovation and a shared passion for improving human health inspires this team to forge ahead with patient interest at the core of everything we do.

Stephen Quake, D. Phil

  • Pioneer in liquid biopsy, single cell genomics, microfluidics
  • Co-President, Chan Zuckerberg Biohub
  • Professor, Bioengineering and applied physics Stanford University
  • Member of all three National Academies – Science, Engineering, and Medicine
  • Past Investigator, Howard Hughes Medical Institute

Alan Ashworth PhD, FRS

  • Cancer biomarkers and therapeutics, DNA repair/synthetic lethality
  • President, Helen Diller Comprehensive Cancer Center
  • SVP for Cancer Services, UCSF Health
  • Professor, Hematology Oncology, UCSF

J.Craig Venter, PhD

  • Pioneer in sequencing Human Genome at Celera Genomics
  • Pioneer in genomic medicine, founder of Human Longevity Inc.
  • Founder of J. Craig Venter Institute

Felix Feng, MD

  • Radiation oncology leader in translational research
  • Significant expertise in identifying and treating aggressive prostate cancer
  • Director, Translational Genomics at University of Michigan, Ann Arbor

Mattias Westman

  • International finance and investments
  • Founding Partner, Prosperity Capital Management
  • Active global cross-border investor
  • Stockholm School of Economics

Stephen Quake, D. Phil

  • Pioneer in liquid biopsy, single cell genomics, microfluidics
  • Co-President, Chan Zuckerberg Biohub
  • Professor, Bioengineering and applied physics Stanford University
  • Member of all three National Academies – Science, Engineering, and Medicine
  • Past Investigator, Howard Hughes Medical Institute

Tina S. Nova, PhD

  • Pioneer in genomic-based molecular diagnostics in oncology
  • President and CEO, Decipher Bio
  • Prior leadership positions in diagnostics companies Molecular Stethoscope, Genoptix (acquired Novartis) Nanogen
  • Biotechnology leadership Illumina and Selective Genetics, Ligand Pharmaceuticals and Hybritech

Dave Mullarkey

  • Life Sciences industry leader with an extensive track record of success in the cell free DNA diagnostics space, DNA sequencing instrument development, and operating in CLIA and IVD environment
  • Proven executive track record of C-level leadership scaling life sciences companies globally to successful exits across pharmaceuticals, diagnostics and life science tools
  • Most recent roles included President and CEO at Omniome, President and COO at Ariosa Diagnostics and Lifecycle Leader and Site Head at Roche
  • Decades of growth-oriented executive experience across different sizes and stages of companies both private and public (Omniome, Roche, Ariosa Diagnostics, Valeant Pharmaceuticals, Johnson & Johnson, Eli Lilly and Company, Dow Pharmaceuticals).

Join Our Team and
Make a Difference